BHCM
RCKT icon

Brevan Howard Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Brevan Howard Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-89,130
Closed -$313K – 2431
2025
Q4 		$313K Buy
+89,130
New +$305K ﹤0.01% 1355
2025
Q1 		– Sell
-25,147
Closed -$316K – 1402
2024
Q4 		$316K Buy
25,147
+8,427
+50% +$127K ﹤0.01% 755
2024
Q3 		$309K Buy
+16,720
New +$342K ﹤0.01% 847

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Brevan Howard Capital Management's RCKT Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 89,130 shares — an estimated $313K sold.

Brevan Howard Capital Management first reported a position in RCKT in Q3 2024 and held it in 3 quarters. The position peaked at $316K in Q4 2024. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 89,130 Rocket Pharmaceuticals shares in Q1 2026, an estimated $313K.
  • Brevan Howard Capital Management first reported a position in Rocket Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Brevan Howard Capital Management's Rocket Pharmaceuticals position peaked at $316K in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.